Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 6/2012

01.06.2012 | Retinal Disorders

Retinal thickness changes following photodynamic therapy in chronic central serous chorioretinopathy

verfasst von: Sergio Copete, Jose M. Ruiz-Moreno, Carlos Cava, Javier A. Montero

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate changes in neural retina (NR) thickness and best-corrected visual acuity (BCVA) induced by treatment of chronic central serous chorioretinopathy (CSC) by photodynamic therapy (PDT).

Patients and methods

Retrospective study of 25 eyes of 25 patients with chronic CSC treated by “full-fluence” PDT. LogMAR BCVA and Stratus optical coherence tomography (OCT) were evaluated before treatment and 1 year after PDT. Twenty-four eyes from 24 patients with non-chronic, non-PDT-treated forms of CSC were evaluated as a control group.

Results

NR foveal thickness before PDT was 182 ± 43.4 μm (range, 92–246) vs 148.1 ± 30.9 μm (range, 101–220) 1 year after treatment (p = 0.004; Student's t-test paired data). NR foveal thickness in the untreated eyes was 204.6 ± 30.7 μ (range, 132–249) vs 192.5 ± 26.4 μ (range, 123–235) after self-resolution (p = 0.03; Student's t-test paired data). Basal NR thickness was statistically significant different between both groups (p = 0.04; Student's t-test); this difference continued to be significant at the end of the follow-up (p < 0.01; Student's t-test). All the patients with chronic CSC treated by PDT showed anatomic resolution, and BCVA improved from 0.38 ± 0.35 to 0.23 ± 0.29 (p = 0.007; Student's t-test paired data). Final BCVA and basal and final NR thickness showed poor correlation (Pearson = 0.2 and 0.1 respectively).

Conclusions

The use of PDT in chronic CSC induces NR thickness thinning. This change is not correlated with a decrease in BCVA. Spontaneous resolution of classic CCS also showed significant NR thinning.
Literatur
1.
Zurück zum Zitat Leaver P, Williams C (1979) Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 63:674–677PubMedCrossRef Leaver P, Williams C (1979) Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 63:674–677PubMedCrossRef
2.
Zurück zum Zitat Robertson DM, Ilstrup D (1983) Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 95:457–466PubMed Robertson DM, Ilstrup D (1983) Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 95:457–466PubMed
3.
Zurück zum Zitat Gilbert CM, Owens SL, Smith PD, Fine SL (1984) Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 68:815–820PubMedCrossRef Gilbert CM, Owens SL, Smith PD, Fine SL (1984) Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 68:815–820PubMedCrossRef
4.
Zurück zum Zitat Ficker L, Vafidis G, While A, Leaver P (1988) Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 72:829–834PubMedCrossRef Ficker L, Vafidis G, While A, Leaver P (1988) Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 72:829–834PubMedCrossRef
5.
Zurück zum Zitat Yannuzzi LA, Slakter JS, Kaufman SR, Gupta K (1992) Laser treatment of diffuse retinal pigment epitheliopathy. Eur J Ophthalmol 2:103–114PubMed Yannuzzi LA, Slakter JS, Kaufman SR, Gupta K (1992) Laser treatment of diffuse retinal pigment epitheliopathy. Eur J Ophthalmol 2:103–114PubMed
6.
Zurück zum Zitat Piccolino FC, Borgia L, Zinicola E, Zingirian M (1995) Indocyanine green angiographic findings in central serous chorioretinopathy. Eye 9:324–332PubMedCrossRef Piccolino FC, Borgia L, Zinicola E, Zingirian M (1995) Indocyanine green angiographic findings in central serous chorioretinopathy. Eye 9:324–332PubMedCrossRef
7.
Zurück zum Zitat Prünte C, Flammer J (1996) Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 121:26–34PubMed Prünte C, Flammer J (1996) Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 121:26–34PubMed
8.
Zurück zum Zitat Parodi MB, Pozzo SD, Ravalico G (2003) Photodynamic therapy in chronic central serous chorioretinopathy. Retina 23:235–237CrossRef Parodi MB, Pozzo SD, Ravalico G (2003) Photodynamic therapy in chronic central serous chorioretinopathy. Retina 23:235–237CrossRef
9.
Zurück zum Zitat Canakis C, Livir-Rallatos C, Panayiotis Z, Livir-Rallatos G, Persidis E, Conway MD, Peyman GA (2003) Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol 136:750–752PubMedCrossRef Canakis C, Livir-Rallatos C, Panayiotis Z, Livir-Rallatos G, Persidis E, Conway MD, Peyman GA (2003) Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol 136:750–752PubMedCrossRef
10.
Zurück zum Zitat Taban M, Boyer DS, Thomas EL, Taban M (2004) Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 137:1073–1080PubMedCrossRef Taban M, Boyer DS, Thomas EL, Taban M (2004) Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 137:1073–1080PubMedCrossRef
11.
Zurück zum Zitat Ober MD, Yannuzzi LA, Do DV, Spaide RF, Bressler NM, Jampol LM, Angelilli A, Eandi CM, Lyon AT (2005) Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology 112:2088–2094PubMedCrossRef Ober MD, Yannuzzi LA, Do DV, Spaide RF, Bressler NM, Jampol LM, Angelilli A, Eandi CM, Lyon AT (2005) Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology 112:2088–2094PubMedCrossRef
12.
Zurück zum Zitat Valmaggia C, Niederberger H (2006) Photodynamic therapy in the treatment of chronic central serous chorioretinopathy. Klin Monatsbl Augenheilkd 223:372–375PubMedCrossRef Valmaggia C, Niederberger H (2006) Photodynamic therapy in the treatment of chronic central serous chorioretinopathy. Klin Monatsbl Augenheilkd 223:372–375PubMedCrossRef
13.
Zurück zum Zitat Tarantola RM, Law JC, Recchia FM, Sternberg P Jr, Agarwal A (2008) Photodynamic therapy as treatment of chronic idiopathic central serous chorioretinopathy. Lasers Surg Med 40:671–675PubMedCrossRef Tarantola RM, Law JC, Recchia FM, Sternberg P Jr, Agarwal A (2008) Photodynamic therapy as treatment of chronic idiopathic central serous chorioretinopathy. Lasers Surg Med 40:671–675PubMedCrossRef
14.
Zurück zum Zitat Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, Klancnik JM Jr, Aizman A (2003) Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 23:288–298PubMedCrossRef Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, Klancnik JM Jr, Aizman A (2003) Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 23:288–298PubMedCrossRef
15.
Zurück zum Zitat Piccolino CF, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM (2003) Photodynamic therapy for chronic central serous chorioretinopathy. Retina 23:752–763CrossRef Piccolino CF, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM (2003) Photodynamic therapy for chronic central serous chorioretinopathy. Retina 23:752–763CrossRef
16.
Zurück zum Zitat Moon JW, Yu HG, Kim TW, Kim HC, Chung H (2009) Prognostic factors related to photodynamic therapy for central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 247:1315–1323PubMedCrossRef Moon JW, Yu HG, Kim TW, Kim HC, Chung H (2009) Prognostic factors related to photodynamic therapy for central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 247:1315–1323PubMedCrossRef
17.
Zurück zum Zitat Ruiz-Moreno JM, Lugo FL, Armadá F, Silva R, Montero JA, Arevalo JF, Arias L, Gómez-Ulla F (2010) Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmol 88:371–376PubMed Ruiz-Moreno JM, Lugo FL, Armadá F, Silva R, Montero JA, Arevalo JF, Arias L, Gómez-Ulla F (2010) Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmol 88:371–376PubMed
18.
Zurück zum Zitat Reinke MH, Canakis C, Husain D, Michaud N, Flotte TJ, Gragoudas ES, Miller JW (1999) Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology 106:1915–1923PubMedCrossRef Reinke MH, Canakis C, Husain D, Michaud N, Flotte TJ, Gragoudas ES, Miller JW (1999) Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology 106:1915–1923PubMedCrossRef
19.
Zurück zum Zitat Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF (2010) Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 117:1792–1799PubMedCrossRef Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF (2010) Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 117:1792–1799PubMedCrossRef
20.
Zurück zum Zitat Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H (2002) Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 43:830–841PubMed Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H (2002) Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 43:830–841PubMed
21.
Zurück zum Zitat Schmidt-Erfuth U, Laqua H, Schlötzer-Schrehardt U, Vistenz A, Naumann GOH (2002) Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 120:835–844 Schmidt-Erfuth U, Laqua H, Schlötzer-Schrehardt U, Vistenz A, Naumann GOH (2002) Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 120:835–844
22.
Zurück zum Zitat Bressler NM (2001) Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2:198–207 Bressler NM (2001) Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2:198–207
23.
Zurück zum Zitat Verteporfin in Photodynamic Therapy (VIP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. – Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541–560CrossRef Verteporfin in Photodynamic Therapy (VIP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. – Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541–560CrossRef
24.
Zurück zum Zitat Fine SL, Patz A, Orth DH, Klein ML, Finkelstein D, Yassur Y (1976) Subretinal neovascularization developing after prophylactic argon laser photocoagulation of atrophic macular scars. Am J Ophthalmol 82:352–357PubMed Fine SL, Patz A, Orth DH, Klein ML, Finkelstein D, Yassur Y (1976) Subretinal neovascularization developing after prophylactic argon laser photocoagulation of atrophic macular scars. Am J Ophthalmol 82:352–357PubMed
25.
Zurück zum Zitat Varley MP, Frank E, Purnell EW (1988) Subretinal neovascularization after focal argon laser for diabetic macular edema. Ophthalmology 95:567–573PubMed Varley MP, Frank E, Purnell EW (1988) Subretinal neovascularization after focal argon laser for diabetic macular edema. Ophthalmology 95:567–573PubMed
26.
Zurück zum Zitat Lewis H, Schachat AP, Haimann MH, Haller JA, Quinlan P, von Fricken MA, Fine SL, Murphy RP (1990) Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 97:503–510PubMed Lewis H, Schachat AP, Haimann MH, Haller JA, Quinlan P, von Fricken MA, Fine SL, Murphy RP (1990) Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 97:503–510PubMed
27.
Zurück zum Zitat Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS (2006) Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 90:869–874PubMedCrossRef Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS (2006) Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 90:869–874PubMedCrossRef
28.
Zurück zum Zitat Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS (2008) Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 28:85–93PubMedCrossRef Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS (2008) Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 28:85–93PubMedCrossRef
29.
Zurück zum Zitat Shin JY, Woo SJ, Yu HG, Park KH (2010) Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina 31:119–126CrossRef Shin JY, Woo SJ, Yu HG, Park KH (2010) Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina 31:119–126CrossRef
30.
Zurück zum Zitat Koytak A, Erol K, Coskun E, Asik N, Oztürk H, Ozertürk Y (2010) Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. Retina 30:1698–1703PubMedCrossRef Koytak A, Erol K, Coskun E, Asik N, Oztürk H, Ozertürk Y (2010) Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. Retina 30:1698–1703PubMedCrossRef
31.
Zurück zum Zitat Wang MS, Sander B, Larsen M (2002) Retinal atrophy in idiopathic central serous chorioretinopathy. Am J Ophthalmol 133:787–793PubMedCrossRef Wang MS, Sander B, Larsen M (2002) Retinal atrophy in idiopathic central serous chorioretinopathy. Am J Ophthalmol 133:787–793PubMedCrossRef
32.
Zurück zum Zitat Husain D, Kramer M, Kenny AG, Michaud N, Flotte TJ, Gragoudas ES, Miller JW (1999) Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 40:2322–2331PubMed Husain D, Kramer M, Kenny AG, Michaud N, Flotte TJ, Gragoudas ES, Miller JW (1999) Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 40:2322–2331PubMed
33.
Zurück zum Zitat Schlötzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U (2002) Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 240:748–757PubMedCrossRef Schlötzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U (2002) Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 240:748–757PubMedCrossRef
34.
Zurück zum Zitat Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87:1453–1458PubMedCrossRef Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87:1453–1458PubMedCrossRef
35.
Zurück zum Zitat Forte R, Cennamo GL, Finelli ML, de Crecchio G (2009) Comparison of time domain Stratus OCT and spectral domain SLO/OCT for assessment of macular thickness and volume. Eye 23:2071–2078PubMedCrossRef Forte R, Cennamo GL, Finelli ML, de Crecchio G (2009) Comparison of time domain Stratus OCT and spectral domain SLO/OCT for assessment of macular thickness and volume. Eye 23:2071–2078PubMedCrossRef
Metadaten
Titel
Retinal thickness changes following photodynamic therapy in chronic central serous chorioretinopathy
verfasst von
Sergio Copete
Jose M. Ruiz-Moreno
Carlos Cava
Javier A. Montero
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 6/2012
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-011-1900-9

Weitere Artikel der Ausgabe 6/2012

Graefe's Archive for Clinical and Experimental Ophthalmology 6/2012 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.